Current Report Filing (8-k)
March 30 2020 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
|
|
CURRENT REPORT
|
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
|
Date of Report (Date of earliest event reported): March 27, 2020
|
|
AIKIDO PHARMA INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-05576
|
52-0849320
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
One Rockefeller Plaza, 11th Floor, New York, NY
|
10020
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (703) 992-9325
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
AIKI
|
The Nasdaq Capital Market
|
On March 27, 2020, AIkido Pharma Inc., a Delaware
corporation (the “Company”), issued a press release (the “Press Release”) announcing that the record date
and distribution date to the Company’s stockholders of shares of Hoth Therapeutics, Inc. (“Hoth”) will be deferred
because of the requirement that the shares be registered prior to distribution. AIkido will provide a record date and distribution
date for the distribution of the shares promptly once the registration statement is declared effective and will issue an update
to stockholders in two weeks on the status of this matter.
A copy of the Press Release is attached hereto
as Exhibit 99.1 and is incorporated by reference in this Current Report.
Item 9.01. Financial Statements and Exhibits
d) Exhibits.
The exhibit listed in the
following Exhibit Index is filed as part of this Current Report on Form 8-K.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated March 27, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AIKIDO PHARMA INC.
|
|
|
|
By:
|
/s/ Anthony Hayes
|
|
Name:
Title:
|
Anthony Hayes
Chief Executive Officer
|
Dated: March 27, 2020
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024